NEWS
Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
Cardiol Therapeutics announced positive topline data from its Phase II MAvERIC-Pilot study, evaluating CardiolRxTM for treating recurrent pericarditis. The 8-week clinical data showed a significant reduction in pericarditis pain and inflammation. The study involved 27 patients, and 89% continued into the extension phase. Notably, 80% of patients with elevated CRP levels at baseline showed normalization. The primary endpoint revealed a mean pain reduction of 3.7 on the NRS scale. CardiolRxTM was well-tolerated and appears promising for future Phase III trials.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1070Followers
68Following
7362Visitors
Follow
Anil Datta : Price dropped and 10 time stocks traded any guess what happened?
Jaguar8 OP Anil Datta : Always expect shorts to attack
Anil Datta Jaguar8 OP : When shorts attack price normally goes down?
Jaguar8 OP Anil Datta : Definitely.
Anil Datta Jaguar8 OP : Good morning any other stocks you are fallowing Can you share please